No real signals in small-cap stocks yesterday; surprises in biotech stocks today?

Yesterday, small-cap stocks showed widespread volatility, but none had a premium-to-market-cap ratio exceeding 0.1%, indicating that no institutional investors were truly willing to take heavy positions. Today, the biotech stock Capricor breached this threshold.

$Capricor Therap(CAPR.US) Bought 8/21 expiring $12 Put, 1.37 million USD, 3,420 contracts, with an exercise price 38% below the current price. The FDA has scheduled an expert committee review for its Duchenne cell therapy on 7/29, with the PDUFA decision date set for 8/22—the expiration date of this Put falls exactly one day before the PDUFA, fully capturing the AdCom window. On 6/26, the company announced Phase III success, yet the stock dropped nearly 7% on the same day due to the FDA suddenly convening an AdCom. Subsequently, the CFO and General Counsel successively reduced their holdings. With Phase III data meeting targets, someone still dumped OTM Puts at a 38% discount, betting on a failure in the 7/29 expert vote—in summary, the premium-to-market-cap ratio is decent, but following it is purely gambling.

In the semiconductor sector, $Silicon Motion Tech(SIMO.US) Bought 8/21 $280 Call, 735,000 USD, 198 contracts, purchased close to the stock price. Last night, the entire storage sector was trampled by new Korean leverage regulations, with the underlying stock down 7.1%; this Call position was entered against the trend during the afternoon crash of that day. On the same day, massive Call orders for SK Hynix ($56.7M) and SanDisk ($17M long-dated) were all placed on the same storage supply chain. SIMO will release Q2 earnings after market close on 7/29—the strike price is at-the-money, and the expiration crosses the earnings date, which is a standard earnings play. Morgan Stanley called out "DRAM 优于 NAND" in early July, while SIMO's main business is NAND controllers, and sell-side analysts are not backing it—when institutions put real money against the sell-side consensus, I am willing to follow with a small position.

$Figma(FIG.US) saw a sweep of 45,000 next week's $29 Calls worth 1.75 million USD, and 19 minutes later, another 240,000 August $35 legs were added—a two-leg relay executed very quickly. However, breaking it down, the $29 leg expires on 7/24, while Figma's earnings are on 8/5; the weekly leg does not capture the earnings event at all, betting purely on short-term momentum. The underlying stock is currently squeezed between RBC's Hold rating, analysts calling for a 44% valuation premium, and CRO share reductions. To follow such a trade, you must adhere to its rhythm: there is only a chance if the underlying stock sees increased volume approaching $29 before 7/24; otherwise, it expires worthless. Treat it as a small bet on short-term moves, not a holding position.

$Riot Platforms(RIOT.US) August $21 Calls totaled 1.27 million USD across 7,912 contracts, nearly ten times larger than the previous day, looking like big money entering—but on the same day, the short side of the mining machine sector was even more aggressive: $IREN(IREN.US)铺满了 short-to-long duration five-leg Puts, and $Hut 8 Mining(HUT.US) added another 1.37 million USD in Puts, with short volume roughly double that of longs. $Riot Platforms(RIOT.US) itself was sold off last week due to valuation concerns and executive insider selling, and yesterday closed down 6.4%. A Call going against the cluster of sector shorts means the direction could easily be crushed by beta at any time; entering this trade is pure gambling.